3Matta A,Ralhan R.Overview of current and future biologically based targeted therapies inhead and neck squamous cell carcinoma[J].Head Neck Oncol,2009,1:6.
4Simader C,Ritter M,Bolz M,et al.Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration[J].Ophthalmology,2014,121(6):1237-1245.
5Mittendorf EA,Alatrash G,Xiao H,et al.Breast cancer vaccines:ongoing National Cancer Institute-registered clinical trials[J].Expert Rev Vaccines,2011,10(6):755-774.
7Hirsh V.Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lunge cancer[J].Current Oncology,2011,18(3):126-138.
8Lacouture M,Melosky B.Cutaneous reactions to anticancer agents targeting the epidermal growth material protected by copright factor receptor:A dermatology-oncology perspective[J].Skin Therapy Letter,2007,12:1-5.
9Reyes-Habito CM,Roh EK.Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer:Part.Targeted herapy[J].J Am Acad Dermatol,2014,71(2):217.
10Carlmark A,Hawker C,Hult A,et al.New methodologies in the construction of dendritic materials[J].Chem Soc Rev,2009,38(2):352-362.
